In the BioHarmony Drug Report Database

"Preview" Icon

Etidronate

Didronel, Bondronat, Bonviva (etidronic acid) is a small molecule pharmaceutical. Etidronic acid was first approved as Didronel on 1982-01-01. It is used to treat extramammary paget disease, heterotopic ossification, and hypercalcemia in the USA. It has been approved in Europe to treat bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, and hypercalcemia amongst others.

 

Trade Name

 

Bondronat, Bonviva
 

Common Name

 

etidronic acid
 

ChEMBL ID

 

CHEMBL871
 

Indication

 

bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, extramammary paget disease, heterotopic ossification, hypercalcemia, neoplasm metastasis, neoplasms by site, neoplastic processes, postmenopausal osteoporosis, water-electrolyte imbalance, wounds and injuries
 

Drug Class

 

Calcium metabolism regulators

Image (chem structure or protein)

Etidronate structure rendering